RankAlpha logo
Back to Rankings

NUWE

NuwellisC
Nasdaq / Health Care Equipment & Services
Last Price
$4.48-$0.42 (-8.57%)
At close · 2026-11-16
View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1
B+
Bull case
20%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-11-13 · RankAlpha Sentiment Codex
Most likely
B
Base case
40%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-11-13 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-11-13 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-11-13
Recent news sentiment (30D)
-32.0
Negative
Company
-
Unavailable
Macro
-32.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+41.4
Score

AI commentary

The Q3 release offers a mixed operating read-through: stronger margins and pediatric sales but flat overall quarterly sales and ongoing funding risk. The packet's $5.03 November 12 adjusted close is a price anchor, not evidence of the post-release percentage reaction; a reliable pre-release comparison and verified analyst revisions were unavailable. Sentiment metrics are unverified, so the zero placeholders above must not be interpreted as observed neutral readings. This T+1 assessment remains cautious despite strong primary-source coverage.

RankAlpha Sentiment Codex - 2026-11-13
Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact
standard
Confidence
-

AI events

2026-12-31catalystQ3 results test the operating-improvement thesisHigh impact

Q3 sales were $2.2 million, flat year over year despite 20% pediatric growth. Gross margin rose to 69.5% and operating loss narrowed 24% to $2.1 million, but Q3 console sales fell to eight from 12 a year earlier. Whether the larger year-to-date installed base produces recurring circuit sales remains the near-term test. [#SEC-8K-2026-11-12] SEC earnings exhibit

2027-02-11eventAquadex pediatric label-expansion reviewHigh impact

Nuwellis submitted a 510(k) seeking to extend Aquadex use to pediatric patients weighing at least five kilograms. Clearance could expand the addressable population, but neither FDA clearance nor a decision date is established. [#SEC-8K-2026-11-12] SEC earnings exhibit

2027-11-13catalystFunding need despite improved marginsHigh impact

The 10-Q reports $8.3 million of September-end cash, $9.3 million of operating cash used in the first nine months of 2026, and a runway only through Q2 2027 under management's plan. It explicitly anticipates needing additional capital to fund operations through year-end 2027; dilution or unfavorable financing is a material downside catalyst. [#10-Q-2026-11-12] SEC Form 10-Q

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-11-13 • Updated nightlySource: Internal modelMethodology